November 3, 2015
MolecularMD Announces Presentations at Upcoming AACR-NCI-EORTC International Conference
PORTLAND, OR and CAMBRIDGE, MA – November 3, 2015 – MolecularMD, Corp., a molecular diagnostics company that develops custom companion diagnostic products and supports clinical trial services for targeted cancer therapies, today announced that its liquid biopsy capability will be highlighted in a presentation at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place November 5 -9 in Boston, MA. MolecularMD will present a poster describing the use of an amplicon based target enrichment method to study a set of tumor/plasma pairs collected from stage IV colon cancer patients to determine whether amplicon based NGS can be used to profile mutations in ctDNA from colorectal cancer patients.
AACR Presentation Details: Title: Mutation Profiling of Colorectal Cancer ctDNA using AmpliSeq CHP2 Cancer Panel Session ID: Poster Session A Session Title: Biomarkers Date & Time: Friday, November 6, 2015; 12:15 PM – 3:15 PM Location: Exhibit Hall C-D Abstract Number: A29